CCND1 and breast carcinoma: A recent study has demonstrated that the activity of the estrogen receptor α (ERα)-coupled BMI1 signature impacts p16INK4a and cyclin D1 status and correlates with the tumor molecular subtype and biologic behavior in breast cancer [9].